Jennifer Klomp , PhD
Pharmacology & Toxicology
Grand Rapids, MI
Biography
I am an Assistant Professor in the Department of Medicine at Michigan State University College of Human Medicine. My research focuses on understanding and defining methods to target aberrant kinase signaling downstream of oncogenic KRAS in pancreatic cancer. Kinases of interest: ERK, CHK1, SRC; Microscopy, protein engineering, molecular biology.
Education
Doctor of Philosophy , Pharmacology, University of Illinois at Chicago, 2017
Master's of Science, Biology, Central Michigan University, 2007
Bachelor's of Science, Biology/Chemistry, Grand Valley State University, 2004
Employment
Assistant Professor, Henry Ford Health + Michigan State University Health Sciences, East Lansing, 2024 - Present
Postdoctoral Fellow, University of North Carolina, Chapel Hill, 2017 - 2024
PhD Candidate/ Graduate Research Assistant/ Graduate Teaching Assistant, University of Illinois at Chicago, Chicago, 2012 - 2017
Senior Research Technician, Van Andel Research Institute, Grand Rapids, 2007 - 2012
Research/Teaching Assistant, Central Michigan University, Mount Pleasant, 2006 - 2007
Undergraduate Researcher , Grand Valley State University, Allendale, 2003 - 2004
Publications
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer Science Signaling (2025)
YAP signaling promotes resistance to MEK and AKT inhibition in NF1-related MPNSTs (2025)
Systemwide characterization of the ERK program that drives pancreatic cancer (2025)
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers Science (2024)
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer Science (2024)
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature (2024)
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors Cancer Research (2023)
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors Cancer Research (2023)
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer Cancer Research (2023)
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer Genes and Cancer (2023)
Fundings
Integrated Training in Cancer Model Systems
Defining the roles of ERK MAPK in driving KRAS-mutant pancreatic cancer growth
Training Program in Lung Biology and Pathobiology
Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer